192 related articles for article (PubMed ID: 10544072)
1. Current options in treatment of anthracycline-resistant breast cancer.
Kröger N; Achterrath W; Hegewisch-Becker S; Mross K; Zander AR
Cancer Treat Rev; 1999 Oct; 25(5):279-91. PubMed ID: 10544072
[TBL] [Abstract][Full Text] [Related]
2. [Therapy of anthracycline-resistant metastatic breast carcinoma].
Kreienberg R
Praxis (Bern 1994); 1998 Apr; 87(17):573-7. PubMed ID: 9623323
[TBL] [Abstract][Full Text] [Related]
3. Anthracycline- and/or taxane-resistant breast cancer: results of a literature review to determine the clinical challenges and current treatment trends.
Moreno-Aspitia A; Perez EA
Clin Ther; 2009 Aug; 31(8):1619-40. PubMed ID: 19808124
[TBL] [Abstract][Full Text] [Related]
4. Single-agent docetaxel (Taxotere) in randomized phase III trials.
Burris HA
Semin Oncol; 1999 Jun; 26(3 Suppl 9):1-6. PubMed ID: 10426452
[TBL] [Abstract][Full Text] [Related]
5. A unified definition of clinical anthracycline resistance breast cancer.
Pivot X; Asmar L; Buzdar AU; Valero V; Hortobagyi G
Br J Cancer; 2000 Feb; 82(3):529-34. PubMed ID: 10682660
[TBL] [Abstract][Full Text] [Related]
6. Differences in therapeutic indexes of combination metronomic chemotherapy and an anti-VEGFR-2 antibody in multidrug-resistant human breast cancer xenografts.
Klement G; Huang P; Mayer B; Green SK; Man S; Bohlen P; Hicklin D; Kerbel RS
Clin Cancer Res; 2002 Jan; 8(1):221-32. PubMed ID: 11801563
[TBL] [Abstract][Full Text] [Related]
7. Drug resistance in chemotherapy for breast cancer.
Saeki T; Tsuruo T; Sato W; Nishikawsa K
Cancer Chemother Pharmacol; 2005 Nov; 56 Suppl 1():84-9. PubMed ID: 16273361
[TBL] [Abstract][Full Text] [Related]
8. Safety and efficacy of the multidrug-resistance inhibitor biricodar (VX-710) with concurrent doxorubicin in patients with anthracycline-resistant advanced soft tissue sarcoma.
Bramwell VH; Morris D; Ernst DS; Hings I; Blackstein M; Venner PM; Ette EI; Harding MW; Waxman A; Demetri GD
Clin Cancer Res; 2002 Feb; 8(2):383-93. PubMed ID: 11839653
[TBL] [Abstract][Full Text] [Related]
9. The efficacy of chemotherapy with docetaxel and paclitaxel in anthracycline-resistant breast cancer (Review).
Pivot X; Asmar L; Hortobagyi GN
Int J Oncol; 1999 Aug; 15(2):381-6. PubMed ID: 10402251
[TBL] [Abstract][Full Text] [Related]
10. Treatment of refractory metastatic breast cancer with 5-fluorouracil plus levofolinic acid as continuous venous infusion: a phase II study.
Gebbia V; Borsellino N; Testa A; Tirrito M; Varvara F; Cucchiara A; Mauceri G; Girlando A; Ferrara M; Caruso F
Anticancer Res; 1999; 19(4C):3553-7. PubMed ID: 10629652
[TBL] [Abstract][Full Text] [Related]
11. Effects of mitomycin C and carboplatin pretreatment on multidrug resistance-associated P-glycoprotein expression and on subsequent suppression of tumor growth by doxorubicin and paclitaxel in human metastatic breast cancer xenografted nude mice.
Ihnat MA; Nervi AM; Anthony SP; Kaltreider RC; Warren AJ; Pesce CA; Davis SA; Lariviere JP; Hamilton JW
Oncol Res; 1999; 11(7):303-10. PubMed ID: 10757444
[TBL] [Abstract][Full Text] [Related]
12. Phase II study of dexverapamil plus anthracycline in patients with metastatic breast cancer who have progressed on the same anthracycline regimen.
Warner E; Hedley D; Andrulis I; Myers R; Trudeau M; Warr D; Pritchard KI; Blackstein M; Goss PE; Franssen E; Roche K; Knight S; Webster S; Fraser RA; Oldfield S; Hill W; Kates R
Clin Cancer Res; 1998 Jun; 4(6):1451-7. PubMed ID: 9626462
[TBL] [Abstract][Full Text] [Related]
13. Anthracycline resistance: the problem and its current definition.
Gianni L
Semin Oncol; 1997 Aug; 24(4 Suppl 10):S10-11-S10-17. PubMed ID: 9275001
[TBL] [Abstract][Full Text] [Related]
14. [Current trends in pharmacotherapy of breast cancer].
Boér K
Orv Hetil; 2002 Apr; 143(14):725-30. PubMed ID: 11975393
[TBL] [Abstract][Full Text] [Related]
15. Topoisomerase IIalpha gene status and prediction of pathological complete remission after anthracycline-based neoadjuvant chemotherapy in endocrine non-responsive Her2/neu-positive breast cancer.
Orlando L; Del Curto B; Gandini S; Ghisini R; Pietri E; Torrisi R; Balduzzi A; Cardillo A; Dellapasqua S; Veronesi P; Viale G; Goldhirsch A; Colleoni M
Breast; 2008 Oct; 17(5):506-11. PubMed ID: 18456496
[TBL] [Abstract][Full Text] [Related]
16. HER-2 amplification and topoisomerase IIalpha gene aberrations as predictive markers in node-positive breast cancer patients randomly treated either with an anthracycline-based therapy or with cyclophosphamide, methotrexate, and 5-fluorouracil.
Di Leo A; Gancberg D; Larsimont D; Tanner M; Jarvinen T; Rouas G; Dolci S; Leroy JY; Paesmans M; Isola J; Piccart MJ
Clin Cancer Res; 2002 May; 8(5):1107-16. PubMed ID: 12006526
[TBL] [Abstract][Full Text] [Related]
17. Management of metastatic breast cancer: monotherapy options for patients resistant to anthracyclines and taxanes.
Rivera E
Am J Clin Oncol; 2010 Apr; 33(2):176-85. PubMed ID: 19675449
[TBL] [Abstract][Full Text] [Related]
18. Salvage chemotherapy of breast cancer.
Norton L
Semin Oncol; 1994 Aug; 21(4 Suppl 7):19-24. PubMed ID: 8091238
[TBL] [Abstract][Full Text] [Related]
19. Paclitaxel-ifosfamide for anthracycline-resistant advanced breast cancer.
Kellokumpu-Lehtinen P; Lantto A; Kokko R; Elomaa L; Järvenpää R; Lehtinen R; Blomqvist C
Int J Clin Pharmacol Res; 2002; 22(2):47-53. PubMed ID: 12503775
[TBL] [Abstract][Full Text] [Related]
20. Carboplatin in combination therapy for metastatic breast cancer.
Perez EA
Oncologist; 2004; 9(5):518-27. PubMed ID: 15477636
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
